Satish Goel

M.D., F.A.C.C.

Dr. Goel has been in practice since 1997.  Over the years, he has provided arrhythmia management services to a vast number of patients though-out the communities he has served.  Dr. Goel is especially interested in the treatment of atrial fibrillation and has extensive experience in cardiac procedures having successfully performed over 3000 ablations.  Dr. Goel is an experienced Watchman device implanter with approximately 100 implants in the last 2 yrs, and has worked closely with his interventional colleagues to learn and teach the skills involved in performing structural heart disease procedures.  In addition, he has helped establish new Electrophysiology services in 2 different hospitals and has been a principle investigator for over 15 device and drug research studies.

Board Certification

  • Internal Medicine, ABIM 1993
  • Cardiovascular Diseases, ABIM 2018
  • Cardiac Electrophysiology, ABIM 2019

Medical Licensure

  • Florida
  • South Carolina

Professional Experience

1997 – 2019 Electrophysiology Practice
Jacksonville, Florida
Present Electophysiology Specialist
Citrus Cardiology Consultants


1996 – 1997 Fellow, Cardiac Electrophysiology
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, New York
1993 – 1996 Fellowship, Cardiology
Albert Einstein College of Medicine
Bronx, New York
1991 – 1993 Residency, Internal Medicine
Albert Einstein College of Medicine
Bronx, New York
1990 – 1991 Internship, Internal Medicine
Albert Einstein College of Medicine
Bronx, New York
1982 – 1988 Doctor of Medicine
All India Institute of Medical Sciences
Ansari Nagar, New Delhi, India

Research Experience

2018 – Ongoing “Guide-HF” (Hemodynamic Guided Management of Heart Failure), Abbott, Sub-Investigator
2018 – Ongoing “ANTHEM-HFrEF” (Autonamic Regulation Therapy to Enhance Myocardial Function and Reduce
Progression of Heart Failure with Reduced Ejection Fraction) LivaNova, Sub-Investigator
2018 – Ongoing Preserved-HF (Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status
in Patients with Type II Diabetes, and Preserved Ejection Fraction Heart Failure), Astra Zeneca, Sub-Investigator
2016 – Ongoing Embrace-HF (EMpagliflozin evaluation By measuRing ImpAct on HemodynamiCs  in
Patients with diabetEs and Heart Failure) Astra Zeneca, Sub-Investigator
2016 – Ongoing Define-HF (Dapagliflozin EFect on symptoms and biomarkers IN diabetEs patients
with Heart Failure) Astra Zeneca, Sub-Investigator
2016 – 2018 Pioneer HF (A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group,
Active-Controlled 8 week study to Evaluate the Effect of Sacubitril/valsartan (LCZ696) versus Enalapril on Changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to Enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure. Sub-Investigator, Novartis
2016 – Ongoing Dal-GenE Trial, A Phase III, Double-Blind, Randomized, Placebo-Controlled study to evaluate the Effects of Dalcetrapib on Cardiovascular (CV) risk in a
genetically defined Population with a Recent Acute Coronary Syndrome (ACS), Sub-Investigator, DalCor Pharmaceuticals
2015 – Ongoing ADAPT RESPONSE  (Resynchronization Therapy CRT in Heart Failure with CRT devices with
AdaptivCRT® (aCRT) algorithm, Principal Investigator, Medtronic, Inc.
2013 – 2017 ANALYZE ST (ST Monitoring to Detect ACS Events in ICD Patients) Principal-Investigator, St. Jude Medical
2013 – Ongoing LSS-4-SITE: The Longitudinal Surveillance Study of the 4-SITE Lead/Header System, Principal Investigator, Boston Scientific
2013 – 2014 MultiSense: Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients, Principal-Investigator, Boston Scientific


“Is Heart Rate Variability Altered Prior to Non-sustained VT in patients with Dilated Cardiomyopathy?” Satish R.Goel,M. D.;Devin J. Ferrick,M. D.;Thierry  Lejemtel,M. D.;Presented at Cardostim,1996, France.

“Impaired Ventricular Filling and Not ‘Chronotropic Incompetence’ Limits Cardiac Output Rise During Exercise in Patients with Severe Left Ventricular  Failure.,Jamishid Shirani,Laura Demopoulos,Gerardo L. Zullo,Satish R. Goel,M.D.;Thierry H. Lejemtel, M. D.;Albert Einstein College of Medicine,Bronx, New York. Presented AHA,1995.

“Effect of Exercise Training of Heart Rate Variability Parameters in Patients with Congestive Heart Failure.”  Study involves treadmill exercise for five (5) days per week for twelve  (12) weeks after termination of exercise protocol. Satish R.Goel,M.D.;Kevin J. Ferrick,M. D.;Thierry Lejemtel,M. D.; John D. Fisher,M.D. Submitted for NASPE,1997.